- Home
- TIL vs PSNL Comparison
TIL vs PSNL Comparison
Compare TIL & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TIL | PSNL |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.7M | 729.1M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | TIL | PSNL |
|---|---|---|
| Price | $8.50 | $7.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $125.00 | $11.50 |
| AVG Volume (30 Days) | 21.1K | ★ 1.3M |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 52.54 | 33.58 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $69,648,000.00 |
| Revenue This Year | N/A | $16.94 |
| Revenue Next Year | N/A | $36.58 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.67 | $2.83 |
| 52 Week High | $42.75 | $11.50 |
Technical Indicators
Market Signals| Indicator | TIL | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 48.24 | 47.50 |
| Support Level | $8.14 | $6.89 |
| Resistance Level | $9.27 | $7.78 |
| Average True Range (ATR) | 0.43 | 0.54 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 33.03 | 46.69 |
Price Performance
Historical ComparisonAbout TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.